Literature DB >> 20420966

Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management.

Ali K Abu-Alfa1, Anas Younes.   

Abstract

Tumor lysis syndrome (TLS) describes a constellation of biochemical and clinical abnormalities resulting from rapid and massive tumor cell death. TLS is frequently associated with hyperuricemia, hyperkalemia, hyperphosphatemia, and secondary hypocalcemia that may lead to serious clinical complications, including acute kidney injury and cardiac arrest. Identification of tumor- and patient-specific risk factors for TLS and early recognition of laboratory and clinical TLS based on established criteria are essential for preventing TLS and forestalling acute kidney injury. Early collaboration between oncologists and nephrologists will help improve assessment of patients' kidney function and risk factors, paving the way for timely and efficacious interventions. Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20420966     DOI: 10.1053/j.ajkd.2009.10.056

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  29 in total

Review 1.  Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib.

Authors:  Bilal Farooqi; Josh Simmons; Zhonglin Hao
Journal:  J Gastrointest Cancer       Date:  2015-09

Review 2.  Tumor lysis syndrome and primary hepatic malignancy: case presentation and review of the literature.

Authors:  Sean P Zivin; Youssef Elias; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2015-03       Impact factor: 1.513

Review 3.  Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project.

Authors:  Katherine C Allen; Amanda H Champlain; Jonathan A Cotliar; Steven M Belknap; Dennis P West; Jayesh Mehta; Steven M Trifilio
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

4.  Catalase -262C>T polymorphisms in Hungarian vitiligo patients and in controls: further acatalasemia mutations in Hungary.

Authors:  Zsuzsanna Kósa; Zsolt Fejes; Teréz Nagy; Melinda Csordás; Enikő Simics; Eva Remenyik; László Góth
Journal:  Mol Biol Rep       Date:  2011-09-24       Impact factor: 2.316

Review 5.  The tumor lysis syndrome.

Authors:  Scott C Howard; Deborah P Jones; Ching-Hon Pui
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

6.  Tumor lysis syndrome in a solid tumor: a case report of a patient with invasive thymoma.

Authors:  Ji Yun Lee; Sung Hee Lim; Ji Young Lee; Ji Hoon Kim; Ki Hong Choi; Keunchil Park; Jong-Mu Sun; Jin Seok Ahn; Myung-Ju Ahn
Journal:  Cancer Res Treat       Date:  2013-12-31       Impact factor: 4.679

Review 7.  Tumor lysis syndrome: new challenges and recent advances.

Authors:  F Perry Wilson; Jeffrey S Berns
Journal:  Adv Chronic Kidney Dis       Date:  2014-01       Impact factor: 3.620

8.  Successful treatment of a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia complicated by bone marrow necrosis and acute renal insufficiency: A case report.

Authors:  Jieyun Xia; Haiying Sun; Zhiling Yan; Feng Zhu; Kai Zhao; Kailin Xu
Journal:  Mol Clin Oncol       Date:  2018-06-25

9.  One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies.

Authors:  Hamdy A Azim; Sherif Ahmed Bahr; Nermine Shawky Kamal; Mohamed Adel Koura; Rehab Tolba; Heba Abdelmoneem Gad; Ahmad Morsy; Hossameldin Mohsen Attia; Ibraheem Iskander; Ahmed Hammad; Mohammed Farouk Hemed; Mohammed Fathy Abdallah; Kareem Ahmed Sadek; Alaa Hamdi Taha
Journal:  Ecancermedicalscience       Date:  2013-12-10

10.  Admission hyperphosphatemia increases the risk of acute kidney injury in hospitalized patients.

Authors:  Charat Thongprayoon; Wisit Cheungpasitporn; Michael A Mao; Ankit Sakhuja; Stephen B Erickson
Journal:  J Nephrol       Date:  2017-10-03       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.